Correlates of immunity for pneumococcal conjugate vaccines

Vaccine

Volumn 21, Issue 17-18, 2003, Pages 2190-2196

  Lee, Lucia H ^a   Frasch, Carl E ^a   Falk, Lydia A ^b   Klein, David L ^b   Deal, Carolyn D ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Conjugate vaccine; Correlate; Pneumococcal

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CLINICAL IMMUNOLOGY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; INFECTION PREVENTION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SEROTYPE; STATISTICAL ANALYSIS; STREPTOCOCCUS INFECTION;

EID: 0037449054     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00025-2     Document Type: Article

References (35)

1. Black S.B., Shinefield H.R., Fireman B., Hiatt R. Safety, immunogenicity, and efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population: possible implications for optimal use. J. Infect Dis. 165(Suppl 1):1992;S139-S143.
2. Black S.B., Shinefield H.R., Fireman B., Hiatt R., Polen M., Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr Infect Dis. J. 10:1991;97-104.
3. Santosham M., Wolff M., Reid R.et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N. Engl. J. Med. 324:1991;1767-1772.
4. Frasch CE. Regulatory perspectives in vaccine licensure. In: Ellis RW, Granoff DM, editors. Development and clinical uses of Haemophilus influenzae type b conjugate vaccines. New York: Marcel Dekker; 1994. p. 435-53.
5. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Preventing pneumococcal disease among infants and young children. MMWR 2000;49(RR09):1-38.
6. http://www.emea.eu.int/htms/human/epar/epar.htm.
7. Black S.B., Shinefield H., Fireman B.et al. Efficacy. Pediatr Infect Dis. J. 19:2000;187-195.
8. Kayhty H., Ahman H. Bridging phase 2 and phase 3 pneumococcal immunologic data for future combination vaccines. Clin. Infect Dis. 33(Suppl 4):2001;S292-S298.
9. Lee C.J., Banks S.D., Li J.P. Virulence, immunity, and vaccine related to Streptococcus pneumoniae. Crit. Rev. Microbiol. 18:1991;89-114.
10. Bruyn G.A.W., Zegers B.J.M., van Furth R. Mechanisms of host defense against infection with Streptococcus pneumoniae. Clin. Infect Dis. 14:1992;251-262.
11. Gillespie S.H. Aspects of pneumococcal infection including bacterial virulence. J. Med. Microbiol. 28:1989;237-248.
12. Musher D.M., Phan H.M., Watson D.A., Baughn R.E. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for pneumococcal pneumonia. J. Infect Dis. 182:2000;158-167.
13. Romero-Steiner S., Musher D.M., Cetron M.S.et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis. 29:1999;281-288.
14. Musher D.M., Groover J.E., Graviss E.A., Baughn R.E. The lack of association between aging and post-vaccination levels of IgG antibody to capsular polysaccharides of Streptococcus pneumoniae. Clin. Infect Dis. 22:1996;165-167.
15. Siber G.R., Thompson C., Reid G.R.et al. Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease. J. Infect Dis. 165(Suppl 1):1992;S129-S133.
16. Black S., Shinefield H., Fireman B.et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis. J. 19:2000;187-195.
17. Wuorimaa T., Dagan R., Vakevainen M.et al. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J. Infect Dis. 184(9):2001;1211-1215.
18. Capeding MRZ, Puumalainen T, Kayhty H, et al. The effect of a booster dose following primary immunization of an eleven-valent pneumococcal conjugate vaccine in Philippine infants [Abstract P37]. In: Proceedings of the Program and Abstracts of the Second International Symposium on Pneumococci and Pneumococcal Disease. Sun City (South Africa); 19-23 March 2000.
19. Rennels M.B., Edwards K.M., Keyserling H.L.et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 101:1998;604-611.
20. Nurkka A., Ahman H., Korkeila M., Jantti V., Kayhty H., Eskola J. Serum and salivary anti-capsular antibodies in infants and children immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis. J. 20(1):2001;25-33.
21. Mbelle N., Huebner R.E., Wasas A.D., Kimura A., Chang I., Klugman K.P. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal. J. Infect Dis. 180:1999;1171-1176.
22. Eskola J., Kilpi T., Palmu A.et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344(6):2001;403-409.
23. Nahm M.H., Olander J.V., Magyarlaki M. Identification of cross-reactive antibodies with low opsonophagocytic activity for Streptococcus pneumoniae. J. Infect Dis. 176(3):1997;698-703.
24. Goldblatt D., Jadresic L.P., Levinsky R.J., Turner M.W. Antibody responses to pneumococcal capsular polysaccharide: what is being measured? Immunodeficiency. 4(1-4):1993;47-50.
25. Musher D.M., Luchi M.J., Watson D.A., Hamilton R., Baughn R.E. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide. J. Infect Dis. 161(4):1990;728-735.
26. Concepcion N.F., Frasch C.E. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab Immunol. 8(2):2001;266-272.
27. Sun Y., Hwang Y., Nahm M.H. Avidity, potency, and cross-reactivity of monoclonal antibodies to pneumococcal capsular polysaccharide serotype 6B. Infect Immun. 69(1):2001;336-344.
28. Goldblatt D., Vaz A.R., Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J. Infect Dis. 177(4):1998;1112-1115.
29. Borrow R., Goldblatt D., Andrews N., Richmond P., Southern J., Miller E. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J. Infect Dis. 184(3):2001;377-380.
30. Richmond P., Borrow R., Goldblatt D.et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J. Infect Dis. 183(1):2001;160-163.
31. Goldblatt D, Akoto OY, Ashton L, et al. Does one dose of pneumococcal conjugate vaccine induce immunological memory in toddlers? [Abstract 42] In: Proceedings of the Programs and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2000. p. 235.
32. Anttila M., Eskola J., Ahman H., Kayhty H. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J. Infect Dis. 177(6):1998;1614-1621.
33. Anttila M., Eskola J., Ahman H., Kayhty H. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine. 17(15-16):1999;1970-1977.
34. Anderson P., Ingram D.L., Pichichero M.E., Peter G. A high degree of natural immunologic priming to the capsular polysaccharide may not prevent Haemophilus influenzae type b meningitis. Pediatr Infect Dis. J. 19(7):2000;589-591.
35. http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3733t2.htm